Seventh CyberKnife System in South Korea Purchased

CyberKnife for Installation at Gyeongsang National University Hospital Will Expand Patient Access

SUNNYVALE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the Gyeongsang National University Hospital (GNUH) in Jinju, South Korea has purchased a CyberKnife Robotic Radiosurgery System. This marks the seventh System sold in the country and its first equipped with the RoboCouch Patient Positioning System. GNUH is the first national university hospital in the country to purchase the System, allowing patients greater access to the benefits of radiosurgery.

With two decades of history, GNUH, the largest medical facility in the province, has been contributing to improving the health and quality of life of its patients with its 28 professional medical departments. The purchase of the CyberKnife System will initiate the development of a stereotactic radiosurgery practice. The System will be utilized for both intracranial and extracranial treatments, offering a full range of therapeutic options in the community.

According to the World Health Organization (WHO), cancer has been the leading cause of death in the Republic of Korea since 1983. Approximately 110,000 people develop cancer annually in Korea with 64,000 annual fatalities. The government's cancer control policy was started in 1989 when it formulated a plan to establish the National Cancer Centre (NCC). It aims at decreasing cancer mortality in year the 2015 through a comprehensive control program and full government support regarding health equity and alignment with worldwide effort for cancer control.

About the Gyeongsang National University Hospital

The Gyeongsang National University Hospital (GNUH) is a 960-bed critical care medical facility located on the Chilam Campus. It has a staff of more than 950 people and is the largest medical facility in the province. The hospital has 28 clinical departments that provide a wide variety of medical services and treatment therapies. Annually, the hospital treats over 500,000 patients. The hospital also functions as a training and research hospital for GNUH medical students and staff.

About the CyberKnife Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 164 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
08/12/2009
CONTACT: Stephanie Tomei, Senior Manager, Public Relations, +1-408-789-4234, stomei@accuray.com, or Kaman Ng, Marcom Asia, +852 2247-8622, kng@accuray.com, both of Accuray Incorporated
Web Site: http://www.accuray.com